在神经瘤学 (RANO) 针对结质瘤的最新响应评估
Gilbert Youssef1,2,3, Patrick Y Wen4,5,6
1Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Current neurology and neuroscience reports
|January 3, 2024
概括
更新的神经瘤学响应评估 (RANO) 2.0标准为质瘤患者提供了标准化的评估. RANO 2.0 简化了对质瘤类型和治疗方式的反应评估.
科学领域:
- 神经瘤学神经瘤学
- 临床试验方法论 临床试验方法论
- 放射学 放射学是一门学科.
背景情况:
- 标准化反应评估对于质瘤临床试验至关重要.
- 神经瘤学现有响应评估 (RANO) 标准是通过专家共识发展出来的.
- 新的患者数据需要更新评估标准.
研究的目的:
- 引入更新的神经瘤学响应评估 (RANO) 2.0标准.
- 为了在质瘤临床试验中标准化响应评估.
- 为评估质瘤反应提供最新的指导.
主要方法:
- 基于新患者数据的RANO 2.0的开发.
- 在质母细胞瘤患者的基线和辐射后MRI扫描的分析.
- 评估非增强性疾病评估对生存相关性的影响.
主要成果:
- 辐射后的MRI是较高的基线,与治疗前的MRI相比,用于质母细胞瘤.
- 确认扫描在辐射治疗后12周内对新诊断的疾病有益.
- 非增强性疾病评估没有改善PFS/OS相关性.
结论:
- 根据RANO 2.0的建议,无论治疗方式如何,高度质瘤和低度质瘤都应采用统一的标准.
- RANO 2.0 为评估非增强性质瘤和混合性质瘤提供了指导.
- 更新的标准旨在提高结质瘤反应评估的一致性和准确性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...